IPO

Immatics just secured $125M. This cash infusion is a major bet on its pioneering PRAME-targeted therapies and a key signal for the future of oncology.

Galderma secured stringent EU approval to use its Sculptra biostimulator on the body, targeting a billion-dollar market and setting a new industry benchmark.

SoFi's surprise $1.5 billion stock sale sends shares tumbling. Is this a bold play for market dominance or a sign of fintech's increasing capital hunger?

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.

With $15M in new funding and seasoned mining execs on board, Getty Copper is now debt-free and poised to unlock the potential of its vast copper assets.

Gartner's inaugural 4PL Magic Quadrant names Redwood a Visionary, highlighting how tech-driven logistics are reshaping healthcare supply chain resilience.

Endeavour Silver's massive convertible note offering slashes debt and funds its giant Pitarrilla project. A savvy move or a dilution risk for investors?

How Winemaker of the Year Jesse Katz blends record-setting sales, historic vineyards, and philanthropy to disrupt the ultra-premium wine market.

A struggling gaming firm merges with Dogecoin's commercial arm in a $1.09B deal. Is it a visionary pivot or a reverse takeover built on crypto hype?

High internet penetration and modern regulations are creating a fertile digital market, with Expanse Studios' recent expansion showing the way.